Skip to main content

Pred-Moxi-Nepaf Disease Interactions

There are 3 disease interactions with Pred-Moxi-Nepaf (moxifloxacin / nepafenac / prednisolone ophthalmic).

Major

NSAIDs (applies to Pred-Moxi-Nepaf) asthma

Major Potential Hazard, High plausibility.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients. A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs. Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity. NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.

References

  1. "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn (2002):
  2. "Product Information. Nalfon (fenoprofen)." Xspire Pharma (2002):
  3. "Product Information. Indocin (indomethacin)." Merck & Company Inc (2002):
  4. "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories (2002):
  5. "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc (2002):
  6. "Product Information. Clinoril (sulindac)." Merck & Company Inc (2001):
  7. "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical (2001):
  8. "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals (2001):
  9. "Product Information. Relafen (nabumetone)." SmithKline Beecham (2001):
  10. "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals (2001):
  11. "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn (2001):
  12. "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories (2001):
  13. "Product Information. Daypro (oxaprozin)." Searle (2001):
  14. "Product Information. Celebrex (celecoxib)." Searle (2001):
  15. "Product Information. Mobic (meloxicam)." Boehringer-Ingelheim (2001):
View all 15 references
Major

Ophthalmic corticosteroids (applies to Pred-Moxi-Nepaf) ocular infections

Major Potential Hazard, High plausibility.

The use of ophthalmic corticosteroids is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella; fungal diseases of ocular structures; mycobacterial infections, including tuberculosis, of the eye; and any acute, purulent, untreated ocular infections. Corticosteroids may decrease host resistance to infectious agents, thus prolonging the course and/or exacerbating the severity of the infection while encouraging the development of new or secondary infection. In addition, administration of ophthalmic corticosteroids in severe ocular disease, especially acute herpes simplex keratitis, may lead to excessive corneal and scleral thinning, increasing the risk for perforation. In less serious ocular infections, therapy with ophthalmic corticosteroids may be administered but only with caution and accompanied by appropriate antimicrobial agents. Besides compromising host immune response, corticosteroids may also mask the symptoms of infection, thus hindering the recognition of potential ineffectiveness of the antibiotic therapy. If infection does not improve or becomes worse during administration of an ophthalmic corticosteroid, the drug should be discontinued and other appropriate therapy initiated.

References

  1. "Product Information. Vexol (rimexolone ophthalmic)." Alcon Laboratories Inc (2001):
  2. "Product Information. Lotemax (loteprednol ophthalmic)." Bausch and Lomb (2001):
  3. "Product Information. Pred Forte (prednisolone ophthalmic)." Allergan Inc (2001):
  4. "Product Information. Decadron Ocumeter (dexamethasone ophthalmic)." Merck & Company Inc (2001):
  5. "Product Information. FML Ophthalmic Suspension (fluoromethalone ophthalmic)." Allergan Inc, Irvine, CA.
  6. "Product Information. HMS (medrysone ophthalmic)." Allergan Inc (2001):
View all 6 references
Major

Ophthalmic corticosteroids (applies to Pred-Moxi-Nepaf) ocular toxicities

Major Potential Hazard, High plausibility. Applicable conditions: Cataracts, Glaucoma/Intraocular Hypertension

Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves. Therapy with ophthalmic corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure. If these agents are used for more than 10 days, the manufacturers recommend that intraocular pressure be routinely monitored, including in children. The equatorial and posterior subcapsular portions of the lens should be examined for changes.

References

  1. Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42
  2. Godel V, Regenbogen L, Stein R "On the mechanism of corticosteroid-induced ocular hypertension." Ann Ophthalmol 10 (1978): 191-6
  3. Francois J "Corticosteroid glaucoma." Ann Ophthalmol 9 (1977): 1075-80
  4. Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976): 492-5
  5. Butcher JM, Austin M, McGalliard J, Bourke RD "Bilateral cataracts and glaucoma induced by long term use of steroid eye drops." BMJ 309 (1994): 43
  6. "Product Information. Vexol (rimexolone ophthalmic)." Alcon Laboratories Inc (2001):
  7. Leibowitz HM, Bartlett JD, Rich R, Mcquirter H, Stewart R, Assil K "Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids." Arch Ophthalmol 114 (1996): 933-7
  8. Foster CS, Alter G, Debarge LR, Raizman MB, Crabb JL, Santos CI, Feiler LS, Friedlaender MH "Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis." Am J Ophthalmol 122 (1996): 171-82
  9. "Product Information. Lotemax (loteprednol ophthalmic)." Bausch and Lomb (2001):
  10. "Product Information. Pred Forte (prednisolone ophthalmic)." Allergan Inc (2001):
  11. "Product Information. Decadron Ocumeter (dexamethasone ophthalmic)." Merck & Company Inc (2001):
  12. "Product Information. FML Ophthalmic Suspension (fluoromethalone ophthalmic)." Allergan Inc, Irvine, CA.
  13. "Product Information. HMS (medrysone ophthalmic)." Allergan Inc (2001):
View all 13 references

Pred-Moxi-Nepaf drug interactions

There are 110 drug interactions with Pred-Moxi-Nepaf (moxifloxacin / nepafenac / prednisolone ophthalmic).


Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.